Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 14, Issue 9, 2014, Pages 847-856

  Leshem, Eyal ^a,b   Lopman, Ben ^a   Glass, Roger ^c   Gentsch, Jon ^a   Bányai, Krisztián ^d   Parashar, Umesh ^a   Patel, Manish ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE; VIRUS ANTIGEN;

ARTICLE; DRUG EFFICACY; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; ROTAVIRUS; ROTAVIRUS INFECTION; SYSTEMATIC REVIEW; VIRUS STRAIN;

HUMANS; ROTAVIRUS; ROTAVIRUS VACCINES; SPECIES SPECIFICITY;

EID: 84906936966     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70832-1     Document Type: Article

References (53)

1. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012, 379:2151-2161. for the Child Health Epidemiology Reference Group of WHO and UNICEF.
2. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200(suppl 1):S9-15.
3. Gentsch JR, Laird AR, Bielfelt B, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005, 192(suppl 1):S146-S159.
4. Banyai K, Laszlo B, Duque J, et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine 2012, 30(suppl 1):A122-A130.
5. Cilla G, Montes M, Gomariz M, et al. Rotavirus genotypes in children in the Basque Country (North of Spain): rapid and intense emergence of the G12[P8] genotype. Epidemiol Infect 2013, 141:868-874.
6. Japhet MO, Adesina OA, Famurewa O, Svensson L, Nordgren J Molecular epidemiology of rotavirus and norovirus in Ile-Ife, Nigeria: high prevalence of G12P[8] rotavirus strains and detection of a rare norovirus genotype. J Med Virol 2012, 84:1489-1496.
7. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
8. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
9. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
10. Matthijnssens J, Nakagomi O, Kirkwood CD, Ciarlet M, Desselberger U, Van Ranst M Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?. Expert Rev Vaccines 2012, 11:1347-1354.
11. Pitzer VE, Patel MM, Lopman BA, Viboud C, Parashar UD, Grenfell BT Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions. Proc Natl Acad Sci USA 2011, 108:19353-19358.
12. Gurgel RQ, Cuevas LE, Vieira SC, et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis 2007, 13:1571-1573.
13. Matthijnssens J, Bilcke J, Ciarlet M, et al. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol 2009, 4:1303-1316.
14. Kirkwood CD Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs. J Infect Dis 2010, 202(suppl):S43-S48.
15. Grimwood K, Kirkwood CD Human rotavirus vaccines: too early for the strain to tell. Lancet 2008, 371:1144-1145.
16. Rotavirus vaccine access and delivery PATH, (accessed July 17, 2014). http://sites.path.org/rotavirusvaccine/rotavirus-advocacy-and-communications-toolkit/country-introduction-maps-and-list/.
17. Zaman K, Duc Anh D, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
18. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
19. Country and lending groups The World Bank, (accessed Jan 9, 2014). http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
20. Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis 2011, 52:191-199.
21. Snelling TL, Schultz R, Graham J, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009, 49:428-431.
22. Braeckman T, Van Herck K, Meyer N, et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012, 345:e4752.
23. Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013, 132:e25-e33.
24. Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis 2013, 57:13-20.
25. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010, 125:e199-e207.
26. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011, 128:e267-e275.
27. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010, 201:363-369.
28. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010, 340:c2825.
29. Linhares AC, Velázquez FR Rotavirus P[4]G2 in a vaccinated population, Brazil (response). Emerg Infect Dis 2008, 14:864.
30. Gurgel RG, Bohland AK, Vieira SC, et al. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 2009, 137:1970-1975.
31. Justino MC, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr Infect Dis J 2011, 30:396-401.
32. Patel MM, Patzi M, Pastor D, et al. Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ 2013, 346:f3726.
33. Yen C, Figueroa JR, Uribe ES, et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J Infect Dis 2011, 204:783-786.
34. Mast TC, Khawaja S, Espinoza F, et al. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr Infect Dis J 2011, 30:e209-e215.
35. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301:2243-2251.
36. Kirkwood CD, Boniface K, Bishop RF, Barnes GL Australian Rotavirus Surveillance Program: annual report, 2009/2010. Commun Dis Intell Q Rep 2010, 34:427-434.
37. Kirkwood CD, Boniface K, Barnes GL, Bishop RF Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix(R) and RotaTeq(R), into the National Immunization Program of Australia. Pediatr Infect Dis J 2011, 30(1 suppl):S48-S53.
38. Kirkwood CD, Roczo S, Boniface K, Bishop RF, Barnes GL Australian Rotavirus Surveillance Program annual report, 2010/11. Commun Dis Intell Q Rep 2011, 35:281-287. for the Australian Rotavirus Surveillance Group.
39. Nakagomi T, Cuevas LE, Gurgel RG, et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch Virol 2008, 153:591-593.
40. Carvalho-Costa FA, Araujo IT, Santos de Assis RM, et al. Rotavirus genotype distribution after vaccine introduction, Rio de Janeiro, Brazil. Emerg Infect Dis 2009, 15:95-97.
41. Kirkwood CD, Boniface K, Bishop RF, Barnes GL Australian Rotavirus Surveillance Program annual report, 2008/2009. Commun Dis Intell Q Rep 2009, 33:382-388. for the Australian Rotavirus Surveillance Group.
42. Kirkwood CD, Cannan D, Boniface K, Bishop RF, Barnes GL Australian Rotavirus Surveillance Program annual report, 2007/08. Commun Dis Intell Q Rep 2008, 32:425-429. for the Australian Rotavirus Surveillance Group.
43. Esteban LE, Rota RP, Gentsch JR, et al. Molecular epidemiology of group A rotavirus in Buenos Aires, Argentina 2004-2007: reemergence of G2P[4] and emergence of G9P[8] strains. J Med Virol 2010, 82:1083-1093.
44. Franco MA, Angel J, Greenberg HB Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24:2718-2731.
45. Bresee JS, Parashar UD, Widdowson MA, Gentsch JR, Steele AD, Glass RI Update on rotavirus vaccines. Pediatr Infect Dis J 2005, 24:947-952.
46. Vesikari T Rotavirus vaccination: a concise review. Clin Microbiol Infect 2012, 18(suppl 5):57-63.
47. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
48. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr 2010, 169:1379-1386.
49. Linhares AC, Velázquez FR, Pérez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189. the Human Rotavirus Vaccine Study Group.
50. Steele AD, Neuzil KM, Cunliffe NA, et al. Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis 2012, 12:213.
51. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335:1022-1028.
52. Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in US children. N Engl J Med 2011, 365:1108-1117.
53. Gastanaduy PA, Sanchez-Uribe E, Esparza-Aguilar M, et al. Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. Pediatrics 2013, 131:e1115-e1120.